英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
olsalazine 500mg tablets
alliance healthcare (distribution) ltd - olsalazine sodium - oral tablet - 500mg
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
olsalazine 500mg tablets
a a h pharmaceuticals ltd - olsalazine sodium - oral tablet - 500mg
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
olsalazine 500mg tablets
de pharmaceuticals - olsalazine sodium - oral tablet - 500mg
爱尔兰 -
英文 -
HPRA (Health Products Regulatory Authority)
dipentum 500mg tablets
atnahs pharma netherlands b.v. - olsalazine sodium - tablet - 500 milligram(s) - aminosalicylic acid and similar agents; olsalazine
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
olsalazine 250mg/5ml oral suspension
special order - olsalazine sodium - oral suspension - 50mg/1ml
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
olsalazine 250mg/5ml oral solution
special order - olsalazine sodium - oral solution - 50mg/1ml
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
olsalazine 500mg tablets
medihealth (northern) ltd - olsalazine sodium - oral tablet - 500mg
英国 -
英文 -
MHRA (Medicines & Healthcare Products Regulatory Agency)
dipentum 500mg tablets
ucb pharma ltd - olsalazine sodium - oral tablet - 500mg
爱尔兰 -
英文 -
HPRA (Health Products Regulatory Authority)
dipentum 250mg capsules.
ucb pharma limited - olsalazine sodium - capsule - 250 milligram
美国 -
英文 -
NLM (National Library of Medicine)
warfarin sodium tablet
rebel distributors corp - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - warfarin sodium tablets are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. warfarin sodium tablets are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. warfarin sodium tablets are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. anticoagulation is contraindicated in any localized or general physical condition or personal circumstance in which the hazard of hemorrhage might be greater than the potential clinical benefits of anticoagulation, such as: warfarin sodium tablets are contraindicated in women who are or may become pregnant because the drug passes through the placental barrier and may cause fatal hemorrhage to the fetus in utero. furthermore, there have been reports of birth malformations in children born to mothers who